MetaCap

Atea Pharmaceuticals Inc. (AVIR)

NASDAQ: AVIRHealth CareBiotechnology: Pharmaceutical PreparationsUSD

3.96+0.03 (+0.76%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

AVIR stock chart

Technical analysis

Key statistics

All statistics
Market cap
$318.00M
EPS (TTM)
-$1.95
52-week range
2.96 – 6.45
Day range
3.80 – 4.09
Volume / Avg
416.46K / 290.60K
Beta
—

52-week range

$2.96$6.45

AVIR stock today

Shares of Atea Pharmaceuticals (AVIR) finished higher on Nov 20 at $3.96, a gain of 0.76% or $0.03 per share, versus the S&P 500's 3.70% decline. At this level, AVIR sits in the middle of its 52-week range of $2.96 to $6.45: 38.6% below the high, set on Mar 10, 2026 and 33.8% above the low. AVIR is up 10.9% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 33.3%.

Atea Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$1.95), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Atea Pharmaceuticals

Company profile

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Jean-Pierre Sommadossi Ph.D.
Headquarters
Boston, MA
Employees
55
IPO year
2020

Financial highlights

Full financials

Atea Pharmaceuticals reported a net loss of $158.3 million, compared with a loss of $168.4 million a year earlier. Diluted earnings per share came in at -$1.94.

Atea Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue————$351.37M
Growth————+622.49%
Net income$-158.35M$-168.38M$-135.96M$-115.91M$121.19M
EPS (diluted)$-1.94$-2.00$-1.63$-1.39$1.37

Analyst forecast

Forecast

Consensus (3 analysts)

buy

Avg. price target

$9.00+127.27%

  • Strong buy 0
  • Buy 2
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $8.00High $10.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-0.40 vs $-0.51
Surprise
+21.57%

AVIR news

All AVIR news

Atea Pharmaceuticals peers

Health Care sector
AVIR peer companies
CompanyPrice% ChgMarket capCompare
LRMRLarimar Therapeutics Inc.3.14-2.48%$328.55Mvs AVIR
INOInovio Pharmaceuticals Inc.1.76+2.92%$329.66Mvs AVIR
MPLTMapLight Therapeutics Inc.5.94-7.48%$330.12Mvs AVIR
SPRYARS Pharmaceuticals Inc.2.96-11.90%$297.56Mvs AVIR
EVMNEvommune Inc.7.04-2.76%$291.10Mvs AVIR
CTNMContineum Therapeutics Inc. Class A8.68-3.98%$340.83Mvs AVIR
BNTCBenitec Biopharma Inc.7.92-2.76%$285.88Mvs AVIR
GLSIGreenwich LifeSciences Inc.19.25-2.73%$282.56Mvs AVIR

Indexes, lists and sector

Atea Pharmaceuticals stock FAQ

What is Atea Pharmaceuticals's stock price today?

AVIR last traded at $3.96 as of Nov 20, 4:00 PM EST, up 0.76% on the day. Prices are delayed at least 15 minutes.

Who is Atea Pharmaceuticals's CEO?

Dr. Jean-Pierre Sommadossi Ph.D. is the chief executive officer of Atea Pharmaceuticals Inc., which has about 55 employees.

What is the AVIR 52-week high?

The 52-week high for AVIR is $6.45 and the 52-week low is $2.96. The stock is currently 38.6% below its high.

Compare AVIR